An individualized approach in the management of thyroid dysfunction associated with checkpoint inhibitors – a clinical case series
DOI:
https://doi.org/10.2478/AMB-2026-0008Keywords:
checkpoint inhibitors, thyroid dysfunction, hypothyroidism, immune-related adverse eventsAbstract
Abstract. Immune checkpoint inhibitors (ICIs) are a revolutionary class of drugs for the treatment of a number of oncological diseases by harnessing the immune system to counteract malignant cells. However, their use as antitumor agents is accompanied by a wide range of immune-mediated adverse effects, including endocrinopathies. Among the latter, thyroid dysfunction stands out as one of the most common. This article presents six different clinical cases of thyroid damage with an emphasis on thorough clinical examination aided by imaging and precise interpretation of hormonal studies. Тhe management of thyroid-related immune-mediated side effects requires an individualized approach, taking into account the severity and dynamics of the abnormalities, the clinical condition of the patient and the stage of the malignancy.
References
Basudan AM. The Role of Immune Checkpoint Inhibitors in Cancer Therapy. Clin Pract. 2022; 13(1): 22-40.
Husebye ES, Castinetti F, Criseno S, et al. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol. 2022; 187(6): G1-G21.
Castinetti F, Borson-Chazot F. Introduction to expert opinion on endocrine complications of new anticancer therapies. Ann Endocrinol (Paris) 2018; 79:535-8.
Byun DJ, Wolchok JD, Rosenberg LM, et al. Cancer immunotherapy – immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 2017; 13:195–207.
Lugowska I, Teterycz P, Rutkowski P. Immunotherapy of melanoma. Contemp Oncol (Pozn) 2018; 22:61–7.
González-Rodríguez E, Rodríguez-Abreu D, Spanish Group for Cancer Immuno-Biotherapy (GETICA).
Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist 2016; 21:804–16.
Ibrahim R, Saleh K, Chahine C et al. LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy. Biomedicines. 2023; 11(7):1878.
Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncology. 2018; 4: 1721–1728.
Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 2018; 4:173–82.
Elantably D, AI Armashi AR, Hammad F, et al. Immune checkpoint inhibitor-related endocrinopathies: A nationwide population-based study. JCO 2022, 40: 2653-2653.
de Filette J, Andreescu CE, Cools F, et al. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm Metab Res 2019; 51:145–56.
Bai X, Chen X, Wu X, et al. Immune checkpoint inhibitor-associated thyroid dysfunction: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase. European Journal of Endocrinology. 2020; 182:1–9.
Stelmachowska-Banas M, Czajka-Oraniec I. Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review. Endocrine Connections. 2020; 9: R207–R228.
Iyer PC, Cabanillas ME, Waguespack SG et al. Immune-related thyroiditis with immune checkpoint inhibitors. Thyroid. 2018; 28: 1243–1251.
Brancatella A, Viola N, Brogioni S, et al. Graves’ disease induced by immune checkpoint inhibitors: a case report and review of the literature. European Thyroid Journal. 2019; 8:192–195.
Sagiv O, Kandl TJ, Thakar SD, et al. Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor therapy in cancer patients. Ophthalmic Plastic and Reconstructive Surgery. 2019; 35: 50–52.
Yuen K, Samson S, Bancos I, et al. American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach. Endocrine Practice. 2022; 28(7): 719-731.
Li X, Song Z, Chen Y, et al. Immune checkpoint inhibitors-related thyroid dysfunction: influencing factor analysis, prediction model development, and management strategy proposal. Cancer Immunol Immunother 2025, 74 (2).
Lu D, Yao J, Yuan G, et al. Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System. Oncologist. 2022;27(2):e126-e132.
Kennedy OJ, Ali N, Lee R, et al. Thyroid dysfunction after immune checkpoint inhibitors in a single-centre UK pan-cancer cohort: A retrospective study. European Journal of Cancer, 2024; 202, 113949.
Karaviti D, Kani ER, Karaviti E, et al. Thyroid disorders induced by immune checkpoint inhibitors. Endocrine. 2024; 85(1):67-79.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 R. Dimitrova, M. Siderova, Zh. Ruseva (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to share, copy and redistribute the material in any medium or format under these terms.
Journal Acta Medica Bulgarica 
